Insight Molecular Diagnostics Inc. SEC Filings

Insight Molecular Diagnostics (IMDX) filed its Q3 2025 10‑Q, reporting net revenue of $260K versus $115K a year ago and a net loss of $10.9M versus $13.5M. Gross profit was $139K as operating expenses reached $11.2M, including R&D of $3.9M and sales and marketing of $1.4M.

For the nine months, revenue was $2.916M versus $395K last year, with a net loss of $27.3M. Operating cash use was $16.6M. The balance sheet showed cash and cash equivalents of $18.7M, total assets of $43.9M, total liabilities of $53.1M, and a shareholders’ deficit of $9.2M.

Management evaluated going concern and concluded it will have sufficient cash for at least the next 12 months, aided by cost controls and the February 2025 offering that raised $29.1M gross (net proceeds ~$28.7M). Commercial progress included Medicare coverage and a $2,753 per‑result reimbursement for GraftAssureCore and initial RUO kit sales under the Bio‑Rad partnership. Common shares outstanding were 28,664,437 as of November 3, 2025.

Insight Molecular Diagnostics Inc. (IMDX) furnished an 8‑K to announce that it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The Company noted that the information provided under Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor automatically incorporated into other filings except as specifically referenced. IMDX’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMDX.

Insight Molecular Diagnostics (IMDX) reported an insider equity change: the CFO acquired 50,000 shares of Common Stock on 10/31/2025 via the vesting and settlement of performance-based RSUs at a stated price of $0. The vesting was triggered when the company’s public float reached at least $75 million, satisfying the “Baby Shelf” performance condition tied to Form S-3 eligibility.

Following the transaction, the reporting person beneficially owned 201,231 Common shares directly. The RSUs were granted under the company’s 2018 Equity Incentive Plan, with each RSU representing the right to receive one share upon settlement. The filing notes that this milestone resulted in the vesting of 50% of the RSUs granted to the reporting person, subject to continued service.

Insight Molecular Diagnostics Inc. insider report: The company's Chief Financial Officer was granted an option to purchase 235,000 shares of common stock with an exercise price of $3.33 per share. The option was granted on 09/28/2025 and expires on 09/28/2035. Following the grant the reporting person beneficially owns 235,000 underlying shares, held directly. The option vests with 33 1/3% becoming exercisable after one year of continuous service from the grant date and the remaining balance vesting in 24 equal monthly installments thereafter, subject to continued service.

Insight Molecular Diagnostics reporting person Josh Riggs, who is listed as CEO and President and a director, acquired an option to purchase 400,000 shares of common stock on 09/28/2025. The option has an exercise price of $3.33 per share and an expiration date of 09/28/2035. The filing shows the reporting person directly beneficially owns the 400,000 option shares following the transaction. Vesting: 33 1/3% becomes exercisable after one year of continuous service from the grant date, with the remainder vesting in 24 equal monthly installments thereafter, subject to continued service. The Form 4 is signed by Josh Riggs on 09/30/2025.